307 related articles for article (PubMed ID: 8162576)
1. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome.
Grundy PE; Telzerow PE; Breslow N; Moksness J; Huff V; Paterson MC
Cancer Res; 1994 May; 54(9):2331-3. PubMed ID: 8162576
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
4. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.
Mannens M; Devilee P; Bliek J; Mandjes I; de Kraker J; Heyting C; Slater RM; Westerveld A
Cancer Res; 1990 Jun; 50(11):3279-83. PubMed ID: 2159377
[TBL] [Abstract][Full Text] [Related]
6. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
7. Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.
Wittmann S; Zirn B; Alkassar M; Ambros P; Graf N; Gessler M
Genes Chromosomes Cancer; 2007 Feb; 46(2):163-70. PubMed ID: 17099873
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
9. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
10. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors.
Kaneko Y; Homma C; Maseki N; Sakurai M; Hata J
Cancer Res; 1991 Nov; 51(21):5937-42. PubMed ID: 1657374
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
12. A third Wilms' tumor locus on chromosome 16q.
Maw MA; Grundy PE; Millow LJ; Eccles MR; Dunn RS; Smith PJ; Feinberg AP; Law DJ; Paterson MC; Telzerow PE
Cancer Res; 1992 Jun; 52(11):3094-8. PubMed ID: 1317258
[TBL] [Abstract][Full Text] [Related]
13. Der(16)t(1;16)(q21;q13) in Wilms' tumor: friend or foe.
Mathew P; Douglass EC; Jones D; Valentine M; Valentine V; Rowe S; Shapiro DN
Med Pediatr Oncol; 1996 Jul; 27(1):3-7. PubMed ID: 8614388
[TBL] [Abstract][Full Text] [Related]
14. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
[TBL] [Abstract][Full Text] [Related]
15. Nonlinkage of 16q markers to familial predisposition to Wilms' tumor.
Huff V; Reeve AE; Leppert M; Strong LC; Douglass EC; Geiser CF; Li FP; Meadows A; Callen DF; Lenoir G
Cancer Res; 1992 Nov; 52(21):6117-20. PubMed ID: 1356625
[TBL] [Abstract][Full Text] [Related]
16. p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
Overall ML; Spencer J; Bakker M; Dziadek M; Smith PJ
Genes Chromosomes Cancer; 1996 Sep; 17(1):56-9. PubMed ID: 8889507
[TBL] [Abstract][Full Text] [Related]
17. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
18. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at chromosome regions 22q11-12 and 11p15.5 in renal rhabdoid tumors.
Schofield DE; Beckwith JB; Sklar J
Genes Chromosomes Cancer; 1996 Jan; 15(1):10-7. PubMed ID: 8824720
[TBL] [Abstract][Full Text] [Related]
20. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
